REGN 7544
Alternative Names: REGN-7544Latest Information Update: 06 Dec 2024
Price :
$50 *
At a glance
- Originator Regeneron Pharmaceuticals
- Class Monoclonal antibodies; Natriuretic agents
- Mechanism of Action Atrial natriuretic factor receptor A antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Postural orthostatic tachycardia syndrome
- Phase I Cardiovascular disorders
Most Recent Events
- 13 Nov 2024 Phase-II clinical trials in Postural orthostatic tachycardia syndrome in USA (SC) (NCT06593600)
- 23 Sep 2024 Regeneron Pharmaceuticals plans phase II in Hypotension in December 2024 (IV) (NCT06608901) (EudraCT2024-514946-35-00)
- 19 Sep 2024 Regeneron Pharmaceuticals plans a phase II trial for Postural orthostatic tachycardia syndrome (SC) (NCT06593600)